Cocrystal Pharma doses last subject in Phase 1b norovirus study
Cocrystal Pharma said the last subject was dosed in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected late 2026 or early 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.